WuXi Biologics trims holding in subsidiary
Biotechnology company WuXi Biologics Holdings has completed a HK$3.81bn ($487m) sale of a part of its stake in subsidiary WuXi Biologics (Cayman), its second sell-down in the stock in less than three months.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: